HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era.
- DOI
- 10.1155/2012/735392
- Published
- 2012
- Container
- Advances in hematology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1155/2012/735392,
title = {HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era.},
author = {Rodrigo JA and Hicks LK and Cheung MC and Song KW and Ezzat H and Leger CS and Boro J and Montaner JS and Harris M and Leitch HA},
year = {2012},
journal = {Advances in hematology},
doi = {10.1155/2012/735392},
url = {https://doi.org/10.1155/2012/735392}
}RIS
TY - JOUR TI - HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era. AU - Rodrigo JA AU - Hicks LK AU - Cheung MC AU - Song KW AU - Ezzat H AU - Leger CS AU - Boro J AU - Montaner JS AU - Harris M AU - Leitch HA PY - 2012 JO - Advances in hematology DO - 10.1155/2012/735392 UR - https://doi.org/10.1155/2012/735392 ER -
APA
JA, R., LK, H., MC, C., KW, S., H, E., CS, L., J, B., JS, M., M, H., & HA, L. (2012). HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era.. Advances in hematology. https://doi.org/10.1155/2012/735392
Source records
- pubmed · retrieved 2026-09-26T04:10:07.782Z